Grattan Woodson Curriculum Vitae

Posted Tue, 06/14/2011 - 20:28 by admin

Curriculum Vitae

Grattan Crowe Woodson III, M.D., FACP

Principal Office Address

1418 Dresden Dr., Suite 225
Atlanta, Georgia 30319

Office Telephone Numbers

Voice: 404.574.2373
Facsimile: 404.298.5577

Home Address

2476 Burnt Leaf Lane
Decatur, Georgia 30033

Email Address

gwoodson [at] arcenter [dot] net

Web Sites

www.OsteoTest.com, www.ARCenter.net

ACADEMIC AND PROFESSIONAL BACKGROUND
  • Northside High School, Atlanta, Ga. 1970
  • Oglethorpe University, Atlanta, Ga. BS 1976
  • Research Fellowship, Anatomic Pathology, Medical College of Georgia 1978
  • Medical College of Georgia, Augusta, Ga. M.D. 1980
  • Categorical Internship and Residency in Internal Medicine MI Bassett Hospital, Cooperstown, NY 1980–83
  • Clinical Fellow in Medicine, Columbia University College of Physicians and Surgeons, 1980–83
  • Senior Associate, Department of Medicine, Emory University School of Medicine, 1983–86
  • Clinical Instructor of Medicine, Emory University School of Medicine, 1986–present
  • Attending Physician in Internal Medicine, Atlanta Center for Medicine, 1986–97
  • Medical Director, Osteoporosis Center of Atlanta, 1988–present
  • Medical Director, Atlanta Research Center, LLC 1989–present
  • Attending Physician, DeKalb Internal Medicine, LLC 1997–present
  • Medical Director of Women’s Health at the Integral Institute for Women’s Health and Research 2010–present
PROFESSIONAL ORGANIZATIONS
  • Certified by the American Board of Internal Medicine 1983
  • Fellow of the American College of Physicians 1993
  • Member of the American Society for Bone and Mineral Research since 1986
  • Member of the American Society of Internal Medicine since 1988
  • President of the Georgia Chapter of the National Osteoporosis Foundation, 1987–91
  • Member of the Scientific Advisory Board of the National Osteoporosis Foundation
  • Washington, DC 1989–1995
  • Education Committee, Scientific Advisory Board of the National Osteoporosis Foundation 1990–1995
  • Member of the Clinical Society for Bone Densitometry since 2006
  • Member of the Southeastern Regional Scientific Advisory Board of the Better Bones Alliance, Proctor and Gamble Pharmaceuticals and Aventis, 1998–2003
  • Member of the National Internal Medicine Advisory Board, Eli Lilly and Company 2001–2005
  • Member of the US Bazedoxifene Steering Committee, Wyeth Research, 2002–2005
HOSPITAL AFFILIATIONS

Emory University Hospital 1983–l1986

Grady Memorial Hospital 1983–1986

DeKalb Medical Center, Decatur, Georgia since 1986–present

CONTRACT RESEARCH EXPERIENCE
  • 1985–1990
    Coinvestgator
    Sponsor: Norwich Eaton Pharmaceuticals (Division of Proctor and Gamble)
    Protocol: Intermittent cyclical etidronate treatment of postmenopausal
    osteoporosis PMOII
    Drug: Etidronate disodium (Didronel®)
  • 1990–1998
    Principal Investigator
    Sponsor: Sandoz Pharmaceutical
    Protocol: A multi-centered, double-blind, placebo-controlled study to investigate the efficacy of salmon calcitonin nasal spray in the prevention of osteoporotic vertebral fractures, Miacalcin® 320
    Drug: Salmon calcitonin nasal spray (Miacalcin®)
  • 1992–1997
    Principal Investigator
    Sponsor: Sanofi Winthrope
    Protocol: A phase III study of intermittent cyclical tiludronate in the treatment of established post-menopausal osteoporosis, Tiludronate 004
    Drug: Tiludronate (Skelid®)
  • 1992–1996
    Principal Investigator
    Sponsor: Sanofi Winthrope
    Protocol: A phase III study of intermittent cyclical tiludronate in the treatment of post-menopausal women with low bone mineral mass and no vertebral fractures, Tiludronate 0055
    Drug: Tiludronate (Skelid®)
  • 1993–1999
    Principal Investigator
    Sponsor: Proctor and Gamble Pharmaceuticals
    Protocol: A multicenter, randomized, double-blind, placebo-controlled parallel group study to determine the efficacy and safety of risedronate in the treatment of osteoporosis in elderly women, RHN 9193
    Drug: Risedronate (Actonel®)
  • 1993–1995
    Principal Investigator
    Sponsor: Proctor and Gamble Pharmaceuticals
    Protocol: A randomized, double-blind, placebo-controlled, multicenter, parallel group study to determine the efficacy and safety of risedronate in the treatment of postmenopausal osteopenic women, RON 9393
    Drug: Risedronate (Actonel®)
  • 1995–1998
    Principal Investigator
    Sponsor: Merck Human Health
    Protocol: A triple-blind, randomized, placebo-controlled, parallel-group multicenter study to evaluate the safety, tolerability and effect on bone mineral density of 10mg of alendronate sodium for the treatment of postmenopausal osteoporosis in elderly female long term care facility residents, FOS351
    Drug: Alendronate Sodium (Fosamax®)
  • 1996–2000
    Principal Investigator
    Sponsor: Roche
    Protocol: Multi-center, double-blind, placebo-controlled, randomized study on the efficacy and safety of ibandronate during 3 years’ treatment in patients with postmenopausal osteoporosis and vertebral fractures using a continuous oral (2.5 mg daily) and an intermittent oral (20 mg every 2nd day for 24 days every 3 months) dosing regimen, MF4411
    Drug: Ibandronate (Boniva®)
  • 1997–1999
    Principal Investigator
    Sponsor: Merck Human Health
    Protocol: A triple-blind, randomized, placebo-controlled multicenter study to compare efficacy of oral alendronate sodium to intranasal calcitonin-salmon for treatment of postmenopausal osteoporosis (IN-FOCAS), FOS417
    Drug: Alendronate Sodium (Fosamax®)
  • 1998–2000
    Principal Investigator
    Sponsor: Pfizer
    Protocol: Safety and efficacy of droloxifene for preventing bone loss in normal, early postmenopausal women, 174-113
    Drug: droloxifene, raloxifene (Evista®)
  • 1997–1999
    Principal Investigator
    Sponsor: Novartis
    Protocol: A Double-Blind, Placebo Controlled Safety and Efficacy Trial with Transdermal Zolendronate (CGP 42446) in the Treatment of Postmenopausal Osteoporosis, 18
    Drug: Zolendronate (ReClast®)
  • 1998–1999
    Principal Investigator
    Sponsor: Berlex
    Protocol: A mulitcenter, double-blind, randomized, placebo controlled, study to evaluate the safety and efficacy of two doses of estradiol given by continuous transdermal administration in prevention of osteoporosis in postmenopausal women, 96041-B
    Drug: Estradiol (Climara®)
  • 1998–2000
    Principal Investigator
    Sponsor: Merck
    Protocol: A double-blind, randomized placebo-controlled, multi-center study to evaluate upper gastrointestinal tolerability upon rechallange in postmenopausal women with osteoporosis who previously discontinued alendronate due to upper gastrointestinal symptoms.
    Drug: alendronate (Fosamax®)
  • 2001–2005
    Principal Investigator
    Sponsor: Wyeth Research
    Protocol: A Multicenter, Double-Blind, Randomized, Placebo and Raloxifene-Controlled Study to Assess Safety and Efficacy of TSE-424 in the Prevention of Postmenopausal Osteoporosis, W300
    Drug: Bazedoxifene acetate and raloxifene (Evista®)
  • 2001–2005
    Principal Investigator
    Sponsor: Wyeth Research
    Protocol: Fracture Incidence Reduction and Safety of TSE-424 (Bazedoxifene Acetate) Compared to Placebo and Raloxifene in Osteoporotic Postmenopausal Women, W301
    Drug: Bazedoxifene Acetate and raloxifene (Evista®)
  • 2001–2004
    Principal Investigator
    Sponsor: Eli Lilly and Company
    Protocol: Comparison of Raloxifene to Alendronate in Postmenopausal Women with Osteoporosis (H3S-US-GGKO) EVA
    Drug: Raloxifene (Evista®) and alendronate (Fosamax®)
  • 2002–2005
    Principal Investigator
    Sponsor: Amgen
    Protocol: A Randomized, Double-Blind, Placebo-controlled, Multi-Dose Phase 2 Study to Determine the Efficacy, Safety, and Tolerability of AMG 162 in the Treatment of Postmenopausal Women with Low Bone Mineral Density.
    Drug: AMG 162 (denosamab) and alendronate (Fosamax®)
  • 2002–2005
    Principal Investigator
    Sponsor: Novartis
    Protocol: Multinational, multicenter, double-blind, randomized, placebo controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fractures after a hip fracture.
    Drug: Zoledronic Acid (ReClast®)
  • 2003–present
    Principal Investigator
    Sponsor: Eli Lilly and Company
    Protocol: Forteo Observational Study, DANCE Study
    Drug: Teraparatide (Forteo®)
  • 2004–2006
    Principal Investigator
    Sponsor: Aventis
    Protocol: Open-label study to determine how prior therapy with Alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teraparatide, OPTIMIZE Study.
    Drug: Teraparatide (Forteo®)
  • 2004–2007
    Principal Investigator
    Sponsor: Proctor and Gamble Pharmaceuticals
    Protocol: Bone Histomorphometry, Microarchitecture and Matrix Structure in Patients Receiving Long-term Alendronate or Risedronate
    Drug: Risedronate (Actonel®) and alendronate (Fosamax®)
  • 2004–2009
    Principal Investigator
    Sponsor: Eli Lilly and Company
    Protocol: Effects of Arzoxifene on Vertebral Fracture Incidence and of Invasive Breast Cancer Incidence in Post Menopausal Women with Osteoporosis or Low Bone Density (GJAD)
    Drug: Arzoxifene
  • 2002–2005
    Principal Investigator
    Sponsor: Amgen
    Protocol: A Randomized, Double blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women with Low Bone Mineral Density
    Drug: Denosamab
  • 2004–2005
    Principal Investigator
    Sponsor: Roche
    Protocol: A prospective, open-label, multi-center, two-part study to investigate patient satisfaction with monthly dosed ibandronate therapy in women with postmenopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate
    Drug: Ibandronate (Boniva®)
  • 2004–2006
    Principal Investigator
    Sponsor: Roche
    Protocol: A one year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis.
    Drug: Ibandronate (Boniva®)
  • 2005–2007
    Principal Investigator
    Sponsor: Amgen
    Protocol: A Randomized, Double-Blind Study Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis (AMG 162 20040132)
    Drug: Denosamab
  • 2005–2008
    Principal Investigator
    Sponsor: Wyeth Research
    Protocol: A Double-Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety study of Bazedoxifene/Conjugated Estrogens Combinations for Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women (3115A1-304-WW)
    Drug: Bazedoxifene and CCE (Premarin®)
  • 2006–present
    Principal Investigator
    Sponsor: Amgen
    Protocol: An Open-Label, Single-Arm Extension Study to Evaluate the Longer-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density (20050233)
    Drug: Denosumab
  • 2006–2008
    Principal Investigator
    Sponsor: GSK
    Protocol: A parallel, placebo-controlled, randomized (2:1) double-blind study of one year duration to assess the effect of oral Ibandronate 150mg given once monthly verses placebo on lumbar spine bone mineral density in men with osteoporosis. (BON105960) Phase 3
    Drug: Ibandronate (Boniva®)
  • 2006–present
    Principal Investigator
    Sponsor: Merck
    Protocol: A Phase III randomized, placebo-controlled clinical trial to assess the safety and efficacy of MK-0822 to reduce the risk of fracture in osteoporotic postmenopausal women treated with vitamin D and calcium.
    Drug: MK-0822 (Cat-K inhibitor)
  • 2006–present
    Principal Investigator
    Sponsor: Lilly
    Protocol: Addendum B3D-MC-GHCY(1) The Effect of Teriparatide Compared with Risedronate
    on Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures
    Drug: Teraparatide (Forteo®)
  • 2007–2008
    Principal Investigator
    Sponsor: GSK
    Protocol: A Dose-Range Finding Study of SB-751689 in Post-Menopausal Women with Osteoporosis (CR9108963)
    Drug: SB-751689 (Calcium receptor inhibitor)
  • 2008–2009
    Principal Investigator
    Sponsor: Lilly
    Protocol: Community Experience of Subjects with Osteoporosis Using the Forteo B Pen to Self-Administer Once-Daily Teriparatide Therapy (B3D-MC-GHDF)
    Drug: Teraparatide (Forteo®) pen system
Musculoskeletal Pain
  • 1997–1999
    Principal Investigator
    Sponsor: Purdue Pharma
    Protocol: Safety and Efficacy of Buprenorphine TDS (Transdermal Delivery System) 12.5, 25. and 50ug/hr Applied every Seven Days for Sixty Days vs 5mg Oxycodone/325 mg acetomenophen Tablets q6h PRN vs Placebo in Patients with Chronic Back Pain, BP96-102
    Drug: Buprenorphine
  • 1997–1999
    Principal Investigator
    Sponsor: Purdue Pharma
    Protocol: A Long-Term, Open-Label, Clinical Use Safety Study of Buprenorphine TDS (Transdermal Delivery System) 12.5, 25, and 50ug/hr Applied Every 72 hours for the Management of Ongoing Pain Syndromes, BP96-0103
    Drug: Buprenorphine and Oxycodone/Acetomentophen (Percocet®)
  • 1998–1999
    Principal Investigator
    Sponsor: Purdue Pharma
    Protocol: A Comparative Study of Buprenorphine TDS, Oxycodone/Acetomentophen Tablets QID and Placebo in Patients with Chronic Back Pain, BP96-0604
    Drug: Buprenorphine and Oxycodone/Acetomentophen (Percocet®)
  • 2006–2007
    Principal Investigator
    Sponsor: Pfizer
    Protocol: A six week double-blind, randomized, multicenter comparison study of the analgesic effectiveness of Celecoxib 200 mg BID compared to Tramadol Hydrochloride 50 mg QID in subjects with chronic low back pain.
    Drug: Celecoxib (Celebrx®) and tramidol (Ultram®)
  • 2007–l2008
    Principal Investigator
    Sponsor: Wyeth
    Protocol: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive-Design, Efficacy, Safety And Tolerability Study Of 4 Fixed Oral Doses Of Dvs Sr In Adult Outpatients With Fibromyalgia Syndrome (3151A4-327-US)
    Drug: Desvelafaxine Succinate (DVS SR)
  • 2007–2010
    Principal Investigator
    Sponsor: Forest Labs
    Protocol: A Phase III Pivotal, Multi-center, Double-Blind, Randomized, Placebo-Controlled Mono-therapy Study of Milnacipran for Treatment of Fibromyalgia
    Drug: Milnacipran
  • 2008–2009
    Principal Investigator
    Sponsor: Wyeth Research
    Protocol: A Multicenter, Randomized Double-Blind Double-Blind, Placebo-Controlled Pregabalin-Referenced, Parallel-Group, Adaptive Design Study of DVS SR in Adult Female Outpatients With Fibromyalgia Syndrome. (3151A4-2003-US) Phase 2
    Drug: Desvelafaxine Succinate (DVS SR) and pregabalin (Lyirca®)
Women’s Health
  • 1998–2000
    Principal Investigator
    Sponsor: Parke Davis
    Protocol: A Randomized, Double-Blind, Active - and Placebo Controlled, Parallel Group, Multicenter Study Assessing the Safety and Protective Effect on the Endometrium of 4 Dosage Combinations of Norethindrone Acetate Plus Ethinyl Estradiol, 376-401
    Drug: Ethinyl Estradiol and Norethindrone (FemHrt®)
  • 1999–2001
    Principal Investigator
    Sponsor: Parke Davis
    Protocol: A 12-week, randomized, partially-blinded, active and placebo controlled, parallel group, multi-center study assessing the effect of norethendrone acetate plus ethinyl estradiol on endothelial dysfunction in postmenopausal women.
    Drug: norethindrone, ethinyl estradiol, (FemHrt®) raloxifene (Evista®)
  • 1999–2001
    Sub-investigator
    Sponsor: Park Davis – Pfizer
    Protocol: Beyond endorsed lipid lowering with EBCT scanning, BELLES
    Drug: atorvastatin (Lipitor®) and pravastatin (Pravacol®)
  • 2002–2005
    Principal Investigator
    Sponsor: Wyeth Research
    Protocol: A Double-Blind, Randomized, Placebo and Active Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations Postmenopausal Women, (W303) Phase 3
    Drug: Bazedoxifene Acetate and CCE (Premarin®) and raloxifene (Evista®)
  • 2008–2009
    Principal Investigator
    Sponsor: Wyeth Research
    Protocol: A Double-Blind, Randomized, Placebo-Controlled Study Assessing the Safety and Efficacy of DVS SR for the Treatment of Vasomotor Symptoms Associated with Menopause. (3151A2-3353-NA) Phase 3
    Drug: Desvelafaxine Succinate (DVS SR)
  • 2008–2009
    Principal Investigator
    Sponsor: QuatRx Pharmaceuticals
    Protocol: Efficacy And Safety Of Ospemifene In The Treatment Of Moderate To Severe Vaginal Dryness And Vaginal Pain Associated With Sexual Activity, Symptoms Of Vulvar And Vaginal Atrophy (Vva), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study Comparing Oral Ospemifene 60 Mg Daily Dose With Placebo In Postmenopausal Women
    Drug: Ospemifene
Osteoarthritis
  • 1998–1999
    Principal Investigator
    Sponsor: Merck Human Health
    Protocol: A randomized, placebo and active comparator-controlled, parallel group, double blind study to compare the efficacy and safety of MK-0966 tablets vs. nabumetone tablets in patients with osteoarthritis of the knee.
    Drug: rofecoxib (Vioxx®) and nabumetone (Relafen®)
  • 1999–2000
    Principal Investigator
    Sponsor: Searle – Pfizer
    Protocol: Clinical Protocol for the Multicenter, Double-bind, Parallel Group Study Comparing the Effects on Renal Function and the Incidence of Gastrointestinal Ulcer Associated with Valdecoxib 20 mg and 40 mg with that of Naproxen 500 mg bid in Patients with Osteoarthritis or Rheumatoid Arthritis.
    Drug: valdecoxib (Bextra®) and naproxen sodium (Naprosyn®)
  • 1999–2000
    Principal Investigator
    Sponsor: Bayer
    Protocol: A multi-center, double blind, placebo controlled, group comparison study to investigate the efficacy, tolerability and safety of BAY 12,9566 as compared to placebo, in the treatment of patients with mild to moderate osteoarthritis of the knee, over 3 years, #100011
    Drug: BAY 12, 9566 (Metaloprotease inhibitor)
  • 2000–2001
    Principal Investigator
    Sponsor: Merck Research Laboratories
    Protocol: A randomized placebo-controlled, parallel group, double blind study to evaluate the safety and efficacy of rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg n patients with osteoarthritis of the knee or hip.
    Drug: rofenoxib (Vioxx®) and celecoxib (Celebrex®)
  • 2003–2004
    Principal Investigator
    Sponsor: GSK
    Protocol: A Phase III, 12-week, Multicentre, Double-blind, Double-dummy, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group study to investigate the Efficacy and Safety of oral GW406381 1mg, 5mg, 10mg, 25mg and 50mg administered once daily, in adults with Osteoarthritis of the knee.
    Drug: GW406381
  • 2005–2006
    Principal Investigator
    Sponsor: Pfizer
    Protocol: Double-Blind, Parallel-Group, Randomized, Study Of The Efficacy And Safety Of Continuous Use Of Celecoxib Vs The "Usual Use" Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee Who Require An Anti-Inflammatory Medication For Control Of Their Pain
    Drug: Celecoxib (Celebrex®)
  • 2005–2006
    Principal Investigator
    Sponsor: NicOX SA
    Protocol: A 13-week, Double-Blind, Parallel, Randomized, Placebo- and Naproxen-controlled HCT 3012-X-301 Efficacy and Safety Study
    Drug: HCT 3012 and naproxen sodium (Naprosyn®)
  • 2006–2007
    Principal Investigator
    Sponsor: NicOX SA
    Protocol: A Parallel, Randomized, Open-Label, Multicenter, 52-week Follow-up Safety Study of HCT 3012 (375 mg bid and 750 mg bid) in Subjects with Osteoarthritis of the Knee.
    Drug: HCT 3012
  • 2007–2008
    Principal Investigator
    Sponsor: Purdue Pharma
    Protocol: BUP 3025: A Multi-center, Randomized, Double-blind, Placebo-controlled Study with an Open-label Run-in to Assess the Efficacy, Tolerability, and Safety of BTDS 10 or BTDS 20 Compared to Placebo in Opioid-naïve Subjects with Moderate to Severe, Chronic Pain due to Osteoarthritis of the Knee
    Drug: Buprenorphine
Publications
Journal Articles

D. Hewitt, G. Woodson, L. L. Vacca A comparison of methods to localize peroxidase
activity in erythrocytes and immunoperoxidase procedures. GA J Science, 1978;3:101.

L. L. Vacca, D. Hewitt, G. Woodson, A comparison of methods using diaminobenzidine
(DAB) to localize peroxidase in erythrocytes, neutrophils, and peroxidase-antiperoxidase
complex. Stain Tech, 1978;53:331-336.

G. Woodson, Coherence therapy with phosphate and etidronate for osteoporosis: preliminary
results. in Osteoporosis 1987, Proceedings of the Second International Symposium on
Osteoporosis Aalborg, Denmark pp. 1188-1189

N. B. Watts, G. Woodson, S. O'Neal, B.D. Catherwood Serum bone Gamma-carboxyglutamate-
containing protein (BGP) declines with time after menopause but does not correlate with
age. Abstract, Clinical Research, 1989;37.

G. Woodson, Coherence therapy increases bone mass. Abstract, J Bone Min Res 1989: Supp 1.

N. B. Watts, S. T. Harris, H. K. Genant, R. D. Wasnich, P. D. Miller, R. D. Jackson, A. A.
Licata, P. D. Ross, G. C. Woodson, M. J. Yanover, W. J. Mysiw, L. Kohse, M. B. Rao, P.
Steiger, B. Richmond, C. H. Chestnut, Intermittent cyclical etidronate treatment of
postmenopausal osteoporosis. N Eng J Med 1990;323;73-79.

G. Woodson, Etidronate combined with estrogen increases bone mass in osteopenia and
osteoporosis. in Osteoporosis 1990, Proceedings of the third International Symposium
on Osteoporosis Copenhagen, Denmark 14-20 October 1990 Eds Claus Christiansen and
Kirsten Overgaard, pp 1476-1478.

S. M. Ott, G. C. Woodson, W. E. Huffer, Bone histomorphometric changes in women with
postmenopausal osteoporosis treated with etidronate. in Osteoporosis 1990, Proceedings
of the Third International Symposium on Osteoporosis Copenhagen, Denmark 14-20 October
1990 Eds Claus Christiansen and Kirsten Overgaard, pp 1318-1322.

G. Woodson, Carlson LM, Treating osteoporosis: the etidronate option. Senior Patient
1991;3:8-15.

S.M. Ott, G. C. Woodson, W.E. Hufer, P.D. Miller, N.B. Watts, Effects of etidronate and
phosphate on bone histomorphology in women with postmenopausal osteoporosis. Abstract
#561, J Bone Min Res August 1991 (supp 1) pp s224.

G. Woodson, Three effective treatments for osteoporosis. Abstract presented at the Adult
Bone and Mineral Working Group of the ASBMR, Tampa Sept 1993, J Bone Min Res 1993;s403.

Susan M. Ott, Grattan C. Woodson, William E. Huffer, Paul D. Miller, Nelson B. Watts,
Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium
in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 1994;78:968-972.

Woodson,G., Phosphate depletion, osteomalacia, and aluminum intoxication due to antacid use
in a patient with normal renal function. Oral presentation at the Adult Bone and Mineral
Group of the ASBMR, Baltimore, MD September 1995. J Bone Min Res 1995:(supp 1):

Woodson,G., Adequate screening for axial osteoporosis with densitometry requires measurement
of the hip and spine. Poster presentation at the ASBMR, Baltimore, MD September 1995. J Bone
Min Res 1995;(supp 1):

M McClung, W Benson, M Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P Miller,
E Pavlov, S Silverman, G Woodson, K Kalkner, P Bekker,. Risedronate treatment of postmenopausal
women with low bone mass: Preliminary Data. Osteoporosis Int 1996; (suppl 1):PTu 700

Woodson, GC.,. An effectiveness study of etidronate therapy with and without estrogen. J Bone
Min Res 1996;(supp 1):M651

P Beeker, M McClung, W Benson, M Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang,
P Miller, E Pavlov, S Silverman, GC Woodson, K Kalkner, D Axelrod,. Risedronate is effective
in increasing BMD in both early and late postmenopausal women with low bone mass. J Bone Min
Res 1997;(suppl 1): S474

McClung, M, W Benson, M Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P
Miller, E Pavlov, S Silverman, GC Woodson, K Kalkner, P Bekker, D Axelrod,. Risedronate
increases BMD at the hip and spine in postmenopausal women with low bone mass. J Bone Min
Res 1997;(suppl 1): P269

Woodson, GC., The diagnosis of osteoporosis using the NHANES II Vs the Hologic normative
data for the femoral neck., J Bone Min Res 1997;(suppl 1): S531

Woodson, GC., The supine lateral site is more sensitive for the diagnosis of osteoporosis
than other axial DXA sites. J Bone Min Res 1997;(suppl 1): F614

Woodson, GC., An interesting case of osteomalacia due to antacid use associated with
stainable bone aluminum in a patient with normal renal function. Bone 1998; 22:6;695-985.

Silverman S, Genant HK, Kiel DP, Maricic MJ, Peacock M, Woodson GC., Salmon-Calcitonin nasal
spray prevents fractures in established osteoporosis. Additional interim fracture analysis of
the “PROOF” study. 1998 Bone; 23(suppl 5)

Chestnut C, Maricic MJ, Silverman S, Woodson GC., Are bone mineral density and biomarkers
good predictors of efficacy for prevention of osteoporotic fractures? — Salmon-calcitonin
nasal spray and alendronate. 1998 Bone; 23(suppl 5)

Woodson GC., DXA T-score Concordance and Discordance between the PA Spine and the Total Hip
Sites. (Oral presentation ASBMR 10-1-99, St Louis, MO) 1999, JBMR 14;suppl 1:#1027, S139

Rosen CJ, Bonnick SL, Miller PD, McClung MR, Wasnich RD, Weiss SR, Woodson GC, Schnitzer TJ,
Lenihan JP, Ross RP, Wang L, Smith ME, Gormley GJ, Melton, ME., Treatment of osteoporosis
in postmenopausal women: alendronate vs intranasal spray calcitonin (effect on bone markers).
1999, JBMR 14;suppl 1:# SA 364, S399.

Rosen CJ, Bonnick SL, Miller PD, McClung MR, Wasnich RD, Weiss SR, Woodson GC, Schnitzer TJ,
Lenihan JP, Ross RP, Wang L, Smith ME, Gormley GJ, Melton, ME., ., Treatment of osteoporosis
in postmenopausal women: alendronate vs intranasal spray calcitonin (effect on BMD) 1999,
JBMR 14;suppl 1:# S365, S400.

Fogelman I, Moreland L, Woodson GC, Mellstrom D, Boling E, Riskin W, Strauss D, Stevens K,
Manhart M., Gastrointestinal side effects and endoscopic findinings similar between risedronate
and placebo-treated patients. 2000 Osteoprosis Int (Suppl 2)1179;459

Woodson GC., Once Weekly Risedronate Therapy. 2000, Osteoporosis Int (suppl 2) s204, 550

Hooper M, Hanley D, Eastell R, Boling B, Ribot C, Woodson GC, Barton I., Sustained Effect
of Risedronate in the Prevention of the First Vertebral Fracture in Women. 2000, J Bone
Min Res (suppl 1) SU400, s428

Josse R, Fogelman I, Woodson GC, Boling E, Stevens K,. Gastrointestinal side effects and
endoscopic findings similar between risedronate and placebo treated patients. 2000, Presented
at the Endocrine Society Meeting, Toronto, CA on 6-12-2000

Woodson, GC., T-score concordance and discordance between the hip and spine measurement
sites. J. Clinical Densitometry, 2000;3:319-324.

Miller P, Woodson GC, Licata AA, Ettinger MP, Mako B, Smith ME, Wang L, Yates J, Melton ME,
Pamisano JJ,. Rechallange of patients who had discontinued alendronate therapy because of
upper gastrointestinal symptoms. 2000, Clin Ther 22;1433-1422.

Woodson GC Risk Factors for Osteoporosis in Postmenopausal African American Women 2003, J
Bone and Mineral Res., Supp 1

Woodson, Grattan C., Risk factors for osteoporosis in postmenopausal African–American women.,
Current Medical Research and Opinion, Volume 20, Number 10, 1 October 2004 , pp. 1681-1687(7)

Shergy W, Greenwald W, Woodson G, Chen P, Misurski D, Wagman R. Teriparatide Demonstrates
Early Effects in Postmenopausal Women with Osteoporosis Abstract presentation at the
American Association of Clinical Endocrinologist Meeting (April 28-May 2, 2004 Boston,
Massachusetts) and the Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis
Meeting (May 24-25, 2004 Bethesda, Maryland).

Michael R. McClung, M.D., E. Michael Lewiecki, M.D., Stanley B. Cohen, M.D., Michael A.
Bolognese, M.D., Grattan C. Woodson, M.D. etal, Denosumab in Postmenopausal Women with
Low Bone Mineral Density., N Engl J Med 2006;354:821-31

McClung, Michael R.; Lewiecki, E Michael; Cohen, Stanley B.; Bolognese, Michael A.; Woodson,
Grattan C.; Moffett, Alfred H.; Peacock, Munro; Miller, Paul D.; Lederman, Samuel N.;
Chesnut, Charles H.; Lain, Douglas; Kivitz, Alan J.; Holloway, Donna L.; Zhang, Charlie;
Peterson, Mark C.; Bekker, Pirow J.; for the AMG 162 Bone Loss Study Group Denosumab
in Postmenopausal Women With Low Bone Mineral Density. Gynecology Obstetrical &
Gynecological Survey. 61(6):384-386, June 2006.

P. D. Miller, C. Christiansen, H. C. Hoeck, D.L Kindler; E. M. Lewiecki, G. Woodson, M.
Ciesielska; A. A. Chines; G. Constantine; P. D. Delmas., Efficacy of Bazedoxifene for the
Prevention of Postmenopausal Osteoporosis: Results of a 2-Year, Phase III,
Placebo-and Active-Controlled Study JBMR 2007, Sup 1

P.D. Miller, A.A. Chines, C. Christiansen, H.C. Hoeck, D.L. Kendler, E.M. Lewiecki; G.
C. Woodson, A.B. Levine, G. Constantine; P.D. Delmas., Effects of Bazedoxifene on Bone
Mineral Density and Turnover in Postmenopausal Women: 2-Year Results of a Randomized,
Double-Blind, Placebo- and Active-Controlled Study., J Bone Miner Res. 2008 Apr;23(4):525-35.

T.E. Dufresne, P.A. Chmielewski, J.H. Nurrea, B. Borah, X. Zhoua, R.J. Phipps, G. Woodson,
P.D. Miller., Comparison of bone architecture via micro-ct after long-term treatment with
risedronate and alendronate: A cross-sectional study in women with postmenopausal osteoporosis
Bone; Volume 42, Supplement 1, Page S70 (March 2008)

IR Reid, P Miller, JP Brown, D Kendler, A Fahrleitner-Pammer, I Valter, K Maasalu, M Bolognese,
G Woodson, H Bone, B Ding, RB Wagman, J San Martin, MS Ominsky, DW Dempster on behalf of
the Denosumab Phase 3 Bone Histology Study Group., Effects of Denosumab on Bone
Histomorphometry: The FREEDOM and STAND Studies., 2010 JBMR In Press

Books

Woodson G C., The Bird Flu Preparedness Planner., 15Nov2005 HCI Books, Deerfield, FL

Woodson G C., The Bird Flu Manual., 15Sep2006, Booksurge Publishers, Charleston, SC

Woodson, G C., The Coming Pandemic Catastrophe, 15Aug2008, Booksurge Publishers, Charleston, SC